

ARPIs in Metastatic Hormone Sensitive Prostate Cancer

Number:	Pol 043	Version:	2.1		
Subject:	Patient Care	Distribution:	External		
Authorised by:	Board of Directors	Approved Date:	9 May 2026	Review Date:	May 2027

Purpose and Scope

The attached Prescribing Guide has been developed by the Urological Society of Australia and New Zealand for the use of our urologist members when considering prescribing Androgen Receptor Pathway Inhibitors (ARPIs) for metastatic hormone sensitive prostate cancer.

Policy Statement

The combination of androgen receptor pathway inhibitors and androgen deprivation therapy (ADT) forms the current standard of care for men with metastatic hormone-sensitive prostate cancer (mHSPC). Despite strong evidence supporting this approach, ARPI utilisation remains low, and many patients continue to receive ADT alone—an approach that is now considered suboptimal.

Pharmaceutical Benefits Scheme (PBS) requirements mandate ARPI initiation within six months of starting ADT; any delay may render a patient ineligible for subsidised treatment. **As urologists are responsible for the diagnosis and initial management of prostate cancer and are often best placed to initiate treatment without delay, USANZ strongly endorses urologists commencing an ARPI together with ADT at the time of diagnosis of mHSPC.**

USANZ recognises the valued role of medical oncology colleagues in the multidisciplinary care of men with advanced prostate cancer. Collaborative discussion regarding additional systemic therapies, such as chemotherapy, is encouraged within an MDT setting. However, timely initiation of ARPI therapy should not be deferred pending such referral or review, given the PBS prescribing window and the clear evidence that early combination therapy improves outcomes.

Further prescribing guidance is available in the *USANZ ARPI Prescribing Guide*.

Prescribing Guide

The Prescribing Guide will be mailed to all Australian members to be used as a convenient reference tool. The guide can also be downloaded from the Members Section of the USANZ website.

The QR code on the Prescribing Guide can be scanned to take members to the Guide for Completing HPOS Process.

Related Documents

- Attachment 1: Prescribing Guide printed and digital
- Attachment 2. Member Resource: Guide for Completing the HPOS Process for Prescribing ARPIs
The attached Guide for Completing the HPOS Process for Prescribing ARPIs has been developed to assist members to log into Provider Digital Access (PRODA) and request authority to prescribe.
- Attachment 3: Summary of QR Codes

Roles and responsibilities

- The USANZ Board of Directors is the approval authority for Position Statements and other Policies that relate to patient care.
- The Genitourinary Oncology Specialty Advisory Group (GUSAG) is responsible for the development and review of position statements and policies that relate to genitourinary oncology medical matters and for making recommendations to the Board of Directors.

Revision history

Version	Date	Notes	By
Draft	2024	Drafted in consultation with relevant pharmaceutical companies	GUSAG
1.0	23 Nov 2024	Approved	Board of Directors
1.1	22 Nov 2025	Member resource reviewed to include delegations.	Board of Directors.
2.0	Dec 2026 -Jan 2026	Further consultation with SAGs and industry. No significant amendments. Approved for release in 2026.	President, CEO
2.1	9 May 2026	Inclusion of Policy Statement	Board of Directors

Review date

This position statement will be reviewed by the Speciality Advisory Group and the Board of Directors. The next review will be in May 2027.

Contact

USANZ President

Email: president@usanz.org.au